Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs
Executive Order On Most-Favored-Nation Pricing Also Foresees Direct Sales
Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.
